单剂量地舒单抗对不育男性精液质量的影响(FITMI研究):随机对照试验的研究方案
FITMI是一项由研究者发起的双盲、安慰剂对照、1:1、单中心随机临床试验,计划在不育男性中比较单剂量地舒单抗60 mg皮下注射与安慰剂对精液质量的影响。受试者按血清AMH作为阳性预测生物标志物筛选,主要结局为入组后一个生精周期(80天)的精子浓度差异。论文描述研究设计,旨在评估地舒单抗能否改善精子生成。
要点
- FITMI为双盲、安慰剂对照、1:1、单中心随机临床试验,比较单剂量地舒单抗60 mg皮下注射与安慰剂。
- 受试者为按血清AMH作为阳性预测生物标志物筛选的不育男性。
- 主要结局为入组后一个生精周期(80天)的精子浓度(百万/mL)差异。
核心结论
- 该研究方案旨在评估地舒单抗能否改善经血清AMH筛选的不育男性的精液质量。
- 研究结果将为该患者群体未来治疗提供关键证据。
研究设计与样本
- FITMI是由申办者兼研究者发起的双盲、安慰剂对照、1:1、单中心随机临床试验。
- 受试者随机接受单剂量地舒单抗60 mg皮下注射或安慰剂。
- 研究在哥本哈根大学医院Rigshospitalet生长与生殖科开展。
- 受试者为按血清AMH作为阳性预测生物标志物筛选的不育男性。
主要发现
- 本文为研究方案,未报告研究结果。
- 主要结局定义为入组后一个生精周期(80天)的精子浓度(百万/mL)差异。
关键数值与推荐
- 单剂量地舒单抗60 mg皮下注射与安慰剂比较。
- 主要结局为入组后一个生精周期(80天)的精子浓度(百万/mL)差异。
- 受试者按血清AMH作为阳性预测生物标志物筛选。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infertility is a common problem globally and impaired semen quality is responsible for up to 40% of all cases. Almost all infertile couples are treated with either insemination or assisted reproductive techniques (ARTs) independent of the etiology of infertility because no medical treatment exists. Denosumab is an antibody that blocks RANKL signaling and inhibition of testicular RANKL signaling has been suggested to improve semen quality in a pilot study. This RCT aims to assess whether treatment with denosumab can improve spermatogenesis in infertile men selected by serum AMH as a positive predictive biomarker. This paper describes the design of the study. METHODS/DESIGN: FITMI is a sponsor-investigator-initiated, double-blinded, placebo-controlled 1:1, single-center, randomized clinical trial. Subjects will be randomized to receive either a single-dose denosumab 60 mg subcutaneous injection or placebo. The study will be carried out at the Department of Growth and Reproduction, Copenhagen University Hospital, Rigshospitalet, Copenhagen. The primary outcome of the study is defined as the difference in sperm concentration (millions pr. mL) one spermatogenesis (80 days) after inclusion. DISCUSSION: We describe a protocol for a planned RCT aimed at evaluating whether treatment with denosumab can improve the semen quality in infertile men selected by using serum AMH as a positive predictive biomarker. The results will provide evidence crucial for future treatment in a patient group where there is a huge unmet need. TRIAL REGISTRATION: Clinical Trials.gov NCT05212337 . Registered on 14 January 2022. EudraCT 2021-003,451-42. Registered on 23 June 2021. Ethical committee H-21040145. Registered on 23 December 2021.
引用
- Yahyavi SK, Holt R, Juel Mortensen L, et al. Effect of a single-dose denosumab on semen quality in infertile men (the FITMI study): study protocol for a randomized controlled trial. Trials. 2022. PMID: 35733213. doi:10.1186/s13063-022-06478-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。